Abstract In September 2006, the US Centers for Disease Control and Prevention (CDC)
released new guidelines calling for routine, voluntary human immunodeficiency virus (HIV) …

Policy discussions about the feasibility of massively scaling up antiretroviral therapy (ART) to
reduce HIV transmission and incidence hinge on accurately projecting the cost of such scale …

Adherence to antiretroviral medications has been shown to be an important factor in
predicting viral suppression and clinical outcomes. The objective of this analysis was to …

Objective: Existing estimates of human immunodeficiency virus (HIV)‐related health state
utilities are inadequate for comparing alternative treatments on the basis of regimen‐specific …

Background: Accurately estimating rates of disease progression is of central importance in
developing mathematical models used to project outcomes and guide resource allocation …

Objective To explore the expected long-term health and economic outcomes of telaprevir
(TVR) plus peginterferon alfa-2a and ribavirin (PR), a regimen that demonstrated …

Objective: To assess the cost-effectiveness of etravirine (INTELENCE), a novel
nonnucleoside reverse transcriptase inhibitor, used in combination with a background …

Objectives. To determine whether gaps exist in published cost-utility analyses as measured
by their coverage of topics addressed in current HIV guidelines from the Department of …

Purpose Despite benefits of antiretroviral therapies (ART), people with HIV infection have
increased risk of cardiovascular disease, kidney disease, and low bone mineral density …

Introduction: Darunavir is a new protease inhibitor (PI) that is co-administered with low-dose
ritonavir and has demonstrated substantial efficacy in clinical trials of highly treatment …